Changes in Expression Levels and Clinical Significance of Park7 and P2X7R in the Serum of Patients with Acute Myocardial Infarction

Xuemei WANG; Haiqing CHEN; Lina CHEN

doi:10.12259/j.issn.2095-610X.S20251117

Volume 46 Issue 11

Nov. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(11): 130-137

Xuemei WANG, Haiqing CHEN, Lina CHEN. Changes in Expression Levels and Clinical Significance of Park7 and P2X7R in the Serum of Patients with Acute Myocardial Infarction[J]. Journal of Kunming Medical University, 2025, 46(11): 130-137. doi: 10.12259/j.issn.2095-610X.S20251117

Citation:

Xuemei WANG, Haiqing CHEN, Lina CHEN. Changes in Expression Levels and Clinical Significance of Park7 and P2X7R in the Serum of Patients with Acute Myocardial Infarction[J]. Journal of Kunming Medical University, 2025, 46(11): 130-137. doi: 10.12259/j.issn.2095-610X.S20251117

Citation:

PDF( 902 KB)

Changes in Expression Levels and Clinical Significance of Park7 and P2X7R in the Serum of Patients with Acute Myocardial Infarction

doi: 10.12259/j.issn.2095-610X.S20251117

1.
Diagnosis and Treatment Center，Chengde Veterans Hospital，Chengde Hebei 067000
2.
Department of Critical Care Medicine，Ninth Eighty-First Hospital of the Joint Logistics Support Force，People’s Liberation Army，Chengde Hebei 067400
3.
Department of Rehabilitation Medicine，Affiliated Hospital of Chengde Medical College，Chengde Hebei 067020，China

Received Date: 2024-12-03
Available Online: 2025-11-01
Publish Date: 2025-11-25

Abstract

Abstract

Objective To investigate the changes in expression levels of Parkinson's disease protein 7 （Park7） and P2X7R purinergic receptor （P2X7R） in the serum of patients with acute myocardial infarction （AMI） and their clinical significance. Methods A total of 145 AMI patients admitted to Chengde Veterans Hospital between February 2021 and May 2023 were recruited as the AMI group. According to the Gensini score for assessing the severity of coronary lesions, they were subdivided into a mild group （≤ 30 points, n = 68）, a moderate group （30-59 points, n = 42）, and a severe group （≥ 60 points, n = 35）. Additionally, 120 healthy volunteers undergoing physical examinations at the same hospital were recruited as the control group. ELISA method was used to measure serum levels of Park7 and P2X7R. Correlation between serum Park7 and P2X7R levels and Gensini score in AMI patients was analysed by Spearman's method. ROC curves were used to evaluate the predictive value of serum Park7 and P2X7R for the occurrence of MACE. Plot Kaplan-Meier curves were plotted to analyze the cumulative MACE incidence rates in patients with different Park7 and P2X7R expression levels. Cox regression analysis was used to identify risk factors for MACE occurrence in AMI patients. Results Compared with the control group, the AMI group showed significantly increased levels of TC, TG, LDL-C, IL-6, CTnI, CK-MB, BNP, and serum P2X7R （P < 0.05）, and significantly decreased levels of serum HDL-C and Park7 （P < 0.05）. Furthermore, statistically significant differences were observed in serum P2X7R and Park7 levels among patients with different severity levels （P < 0.05）. There was a negative correlation between serum Park7 and Gensini score in AMI patients （r = -0.497, P < 0.05）, while a positive correlation between P2X7R level and Gensini score （r = 0.441, P < 0.05）. Serum Park7 level in the MACE group was significantly lower than that in the non MACE group （P < 0.05）, while the P2X7R level was significantly higher （P < 0.05）. The AUCs for serum Park7, P2X7R, and their combination in predicting MACE in AMI patients was 0.851, 0.820, and 0.905, respectively, with the combined prediction demonstrating superior performance （Z_{combination - Park7}=2.324, Z_{combination - P2X7R}=2.538, P < 0.05）. The 6-month cumulative MACE incidence was lower in patients with low Park7 expression （51.22%） than in those with high Park7 expression （80.95%）（Log Rank χ²=12.178, P < 0.001）; conversely, the 6-month cumulative MACE incidence was higher in patients with low P2X7R expression （82.09%） than in those with high P2X7R expression （48.72%）（Log Rank χ²=20.233, P < 0.001）. CTnI, CK-MB, BNP, Park7, and P2X7R were identified as influencing factors for MACE in AMI patients （P < 0.05）. Conclusion Serum Park7 level is downregulated while P2X7Rlevel is upregulated in AMI patients, both closely related to the severity of the disease. The combination of the two has high predictive value for the occurrence of MACE in AMI patients.
- Acute myocardial infarction,
- Parkinson's disease protein 7,
- P2X7 purinergic receptor,
- Clinical significance

FullText(HTML)

References(19)

References

[1]	Krittanawong C, Khawaja M, Tamis-Holland J E, et al. Acute myocardial infarction: Etiologies and mimickers in young patients[J]. J Am Heart Assoc, 2023, 12(18): e029971. doi: 10.1161/JAHA.123.029971
[2]	Gallinat A, Mendieta G, Vilahur G, et al. DJ-1 administration exerts cardioprotection in a mouse model of acute myocardial infarction[J]. Front Pharmacol, 2022, 13: 1002755. doi: 10.3389/fphar.2022.1002755
[3]	Pan G, Yang S, Han X, et al. Parkinson’s disease protein 7 protected against oxidative stress of myocardial infarction direct through p47phox and nicotinamide adenine dinucleotide phosphate oxidase 4[J]. Hum Exp Toxicol, 2022, 41: 09603271221124099.
[4]	Bin Dayel A, Alonazi A, Alshammari T, et al. P2X7 purinergic receptor: A potential target in heart diseases (Review)[J]. Mol Med Rep, 2023, 27(3): 74. doi: 10.3892/mmr.2023.12961
[5]	Shi X X, Zheng K C, Shan P R, et al. Elevated circulating level of P2X7 receptor is related to severity of coronary artery stenosis and prognosis of acute myocardial infarction[J]. Cardiol J, 2021, 28(3): 453-459. doi: 10.5603/CJ.a2020.0074
[6]	孔海英, 杨广龙, 尹琼, 等. 冠状动脉粥样硬化性心脏病病人斑块稳定性及Gensini评分与Lp(a)水平的相关性[J]. 中西医结合心脑血管病杂志, 2022, 20(2): 304-307.
[7]	中国医师协会中西医结合医师分会, 中国中西医结合学会心血管病专业委员会, 中国中西医结合学会重症医学专业委员会, 等. 急性心肌梗死中西医结合诊疗指南[J]. 中国中西医结合杂志, 2018, 38(3): 272-284.
[8]	Saito Y, Oyama K, Tsujita K, et al. Treatment strategies of acute myocardial infarction: Updates on revascularization, pharmacological therapy, and beyond[J]. J Cardiol, 2023, 81(2): 168-178. doi: 10.1016/j.jjcc.2022.07.003
[9]	Sun M E, Zheng Q. The tale of DJ-1 (PARK7): A Swiss army knife in biomedical and psychological research[J]. Int J Mol Sci, 2023, 24(8): 7409. doi: 10.3390/ijms24087409
[10]	Tsoporis J N, Drosatos I A, Gupta S, et al. Cytoprotective mechanisms of DJ-1: Implications in cardiac pathophysiology[J]. Molecules, 2021, 26(13): 3795. doi: 10.3390/molecules26133795
[11]	Pan J, Xiong W, Zhang A, et al. The imbalance of p53-Park7 signaling axis induces iron homeostasis dysfunction in doxorubicin-challenged cardiomyocytes[J]. Adv Sci (Weinh), 2023, 10(15): e2206007. doi: 10.1002/advs.202206007
[12]	Zhao X Y, Ren J M, Liu H R, et al. DJ-1 activates the AMPK/mTOR pathway by binding RACK1 to induce autophagy and protect the myocardium from ischemia/hypoxia injury[J]. Biochem Biophys Res Commun, 2022, 637: 276-285. doi: 10.1016/j.bbrc.2022.10.100
[13]	Lu Y, Zhang J, Han B, et al. Extracellular vesicles DJ-1 derived from hypoxia-conditioned hMSCs alleviate cardiac hypertrophy by suppressing mitochondria dysfunction and preventing ATRAP degradation[J]. Pharmacol Res, 2023, 187: 106607. doi: 10.1016/j.phrs.2022.106607
[14]	Pantner Y, Polavarapu R, Chin L S, et al. DJ-1 attenuates the glycation of mitochondrial complex I and complex III in the post-ischemic heart[J]. Sci Rep, 2021, 11(1): 19408. doi: 10.1038/s41598-021-98722-1
[15]	Chen R, Li W, Qiu Z, et al. Ischemic postconditioning-mediated DJ-1 activation mitigate intestinal mucosa injury induced by myocardial ischemia reperfusion in rats through Keap1/Nrf2 pathway[J]. Front Mol Biosci, 2021, 8: 655619. doi: 10.3389/fmolb.2021.655619
[16]	Tsirebolos G, Tsoporis J N, Drosatos I A, et al. Emerging markers of inflammation and oxidative stress as potential predictors of coronary artery disease[J]. Int J Cardiol, 2023, 376: 127-133. doi: 10.1016/j.ijcard.2023.02.005
[17]	Hirayama Y, Anzai N, Kinouchi H, et al. P2X7 receptors in astrocytes: A switch for ischemic tolerance[J]. Molecules, 2022, 27(12): 3655. doi: 10.3390/molecules27123655
[18]	Huang S, Wang W, Li L, et al. P2X7 receptor deficiency ameliorates STZ-induced cardiac damage and remodeling through PKCβ and ERK[J]. Front Cell Dev Biol, 2021, 9: 692028. doi: 10.3389/fcell.2021.692028
[19]	Cheng W, Sun Y, Wu Q, et al. Paraventricular nucleus P2X7 receptors aggravate acute myocardial infarction injury via ROS-induced vasopressin-V1b activation in rats[J]. Neurosci Bull, 2021, 37(5): 641-656. doi: 10.1007/s12264-021-00641-8